Today was a big day at the European Society of Intensive Care Medicine (ESICM) International Conference. Today was the Hot Topics session with the results from a number of studies being presented, many of which were published online simultaneously with the presentations. I would like to take the opportunity to highlight four such trials presented in this Hot Topics session today: 1) The EMPIRICUS Trial (Empiric Micafungin in critically ill septic patients colonized with candida and with multiple organ dysfunction); 2) The OXYGEN-ICU Trial (Conservative vs. conventional oxygen therapy in ICU patients); 3) LeoPARDS Trial (Levosimendan in Septic Shock); and 4) High Flow Nasal Cannula vs Non-Invasive Ventilation Post-Extubation in High Risk Patients.
Yesterday, I blogged about the first group of clinical trials with results presented at European Society of Intensive Care Medicine International Conference (ESICM Update #1). This blog will try to summarize some of the trials presented in the session on Tuesday, October 4. The four studies from this session that I will briefly discuss include: Long-term outcomes of the TRISS randomized trial, the GRAVITY-VAP trial (lateral trendelenberg vs semirecumbent position to prevent VAP), the CLASSIC trial (restricting resuscitation fluid in patients with septic shock), and the OPERA trial (post-operative high flow nasal cannula vs conventional oxygen in patients after major abdominal surgery).
The European Society of Intensive Care Medicine (ESICM) is conducting its international conference this week. This conference has traditionally been a hotbed for breaking results from clinical trials. In this post, I would like to briefly highlight four clinical trials whose results were presented during the President’s Session of Clinical Trials in Intensive Care yesterday. Specifically, this post will briefly summarize the HYPRESS trial (Hydrocortisone for Prevention of Septic Shock), the DESIRE trial (Dexmedetomidine for ventilated septic patients in ICU), NAVA versus Pressure Support Ventilation, and the MACMAN trial (McGrath VL versus Macintosh DL for orotracheal intubation in intensive care patients).
For those of you who have been following the blog, you might remember that I recently detailed some new studies investigating early mobility in critically ill patients (See blog post here: Is Early Mobility in the ICU at a Standstill?). This week, another new study was published, this one in The Lancet (Schaller SJ, et al. Lancet. 2016;388(10052):1377-1388). This randomized study found benefit from early mobilization in critically ill surgical patients enrolled from 5 international ICUs (3 in US, 1 in Austria, 1 in Germany). I’d like to use this opportunity to discuss the methodology and results of this study and my current thoughts on early mobility in critically ill patients. Continue reading “Update on Early Mobility: New Data. New Thoughts?”